Evidence map›Paper›PMID 42910131›Full record

ArticleInternational journal of medical sciences2026

Efficacy of Unrelated Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia: A Single-Center Retrospective Study.

Jinrong Zhao, Liangliang Wu, Ming Zhou, Xiaowei Chen, Wenjian Mo, Ruiqing Zhou, Yumiao Li, Caixia Wang, Shilin Xu, Shiyi Pan and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jinrong ZhaoDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Liangliang WuDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Ming ZhouDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Xiaowei ChenDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Wenjian MoDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Ruiqing ZhouDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Yumiao LiDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Caixia WangDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Shilin XuDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Shiyi PanDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Wei ZhouDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Tingfen DengDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Yuping ZhangDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Shunqing WangDepartment of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong, China; Department of Hematology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the efficacy of unrelated allogeneic hematopoietic stem cell transplantation (URD-HSCT) in severe aplastic anemia (SAA), this study retrospectively analyzed the clinical data of 206 patients at a single center. The median age was 28 years (range: 5-64 years), and 13.6% had received immunosuppressive therapy prior to transplantation. The median time to neutrophil and platelet engraftment was 12 days (range: 9-22 days / 8-55 days), respectively, with a graft failure rate of 3.4%. The cumulative incidence of grade II-IV acute graft-versus-host disease (aGVHD) was 21.7% (95% CI: 16.6%-27.8%), and that of chronic GVHD was 20.4% (95% CI: 15.4%-26.6%). Survival analysis revealed a 7-year overall survival (OS) rate of 91% for the entire cohort. Notably, the 7-year OS rate was significantly higher in the donor age ≤30 years group compared to the >30 years group (97% vs 85%,

Indexed as

Anemia, AplasticGraft vs Host DiseaseHematopoietic Stem Cell TransplantationAdolescentAdultChildChild, PreschoolDisease-Free SurvivalFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateTransplantation, HomologousTreatment Outcomeaplastic anemiaHSCTOSSAAURD

Identifiers

PMID42910131
PMCPMC13685043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.